31 January 2024
31 January 2024
Dr. Nicholas Finer, former senior principal clinical scientist at Novo Nordisk discusses the changing obesity drugs landscape.
The company’s 2023 revenues declined from those in the previous year primarily due to reduced sales of Covid-19 products.
Vertex is planning to submit a new drug application to the FDA following the announcement of its Phase III programme meeting its primary endpoint.
The combination would be the first non-chemotherapy treatment in the country for patients with locally advanced or metastatic urothelial cancer.
Synthekine will receive an upfront payment of $40m for its preclinical cytokine engineering clinical expertise.
The strategic move comes as Regeneron acquires development and commercialisation rights to 2seventy bio's investigational immune cell therapies pipeline.
The French biotech, which partnered with Sanofi late last year, brings its Series A funding total to $65m.
The investment is aligned with the France 2030 programme, emphasising the optimisation of the biomedicines production chain.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
